A Phase 1 interventional study of crizotinib in Healthy, sponsored by Pfizer. Completed at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-10-24.
Sponsored by Pfizer · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to demonstrate bioequivalence of the Commercial Image Capsule (CIC) relative to the Immediate Release Tablet (IRT) of crizotinib, bioequivalence of CIC relative to Powder in Capsule (PIC) of crizotinib, and lack of an effect of high fat meal on the pharmacokinetics (PK) of crizotinib when administered as CIC Formulation in healthy volunteers.
The purpose of this study is to demonstrate bioequivalence of the CIC relative to IRT and CIC relative to PIC, and lack of an effect of food on the PK of crizotinib in healthy volunteers.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All subjects will receive four treatments in one of the indicated orders: A-B-C-D, B-D-A-C, C-A-D-B, D-C-B-A
Drug: crizotinib
Treatment A (Reference 1): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 50-mg IRT and 2 × 100-mg IRTs. Treatment B (Reference 2): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 50-mg PIC and 2 × 100 mg PICs. Treatment C (Test for BE, Reference for Food Effect): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 250-mg CIC. Treatment D (Test High Fat): a 250 mg single dose of crizotinib administered with a high-fat meal as 1 × 250-mg CIC
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0 - ∞])
AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).
Time frame: 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hours (hrs) post crizotinib dose
Maximum Observed Plasma Concentration (Cmax)
Time frame: 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
Area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration (AUClast).
Time frame: 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame: 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose
Plasma Decay Half Life (t1/2)
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose
Apparent Oral Clearance (CL/F)
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
Time frame: 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose
Apparent Volume of Distribution (Vz/F)
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
Time frame: 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Crizotinib Metabolite (PF-06260182)
Area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration (AUClast) of Crizotinib metabolite (PF-06260182).
Time frame: 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0 - ∞]) for Crizotinib Metabolite (PF-06260182)
AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).
Time frame: 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose
Maximum Observed Plasma Concentration (Cmax) for Crizotinib Metabolite (PF-06260182)
Time frame: 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose
Time to Reach Maximum Observed Plasma Concentration (Tmax) for Crizotinib Metabolite (PF-06260182)
Time frame: 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose
| Milestone | Crizotinib 250 mg IRT Fasted, PIC Fasted, CIC Fasted, CIC Fed | Crizotinib 250 mg PIC Fasted, CIC Fed, IRT Fasted, CIC Fasted | Crizotinib 250 mg CIC Fasted, IRT Fasted, CIC Fed, PIC Fasted | Crizotinib 250 mg CIC Fed, CIC Fasted, PIC Fasted, IRT Fasted |
|---|---|---|---|---|
| Started | 9 | 9 | 9 | 9 |
| Completed | 9 | 9 | 9 | 9 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Crizotinib 250 mg IRT Fasted, PIC Fasted, CIC Fasted, CIC Fed | Crizotinib 250 mg PIC Fasted, CIC Fed, IRT Fasted, CIC Fasted | Crizotinib 250 mg CIC Fasted, IRT Fasted, CIC Fed, PIC Fasted | Crizotinib 250 mg CIC Fed, CIC Fasted, PIC Fasted, IRT Fasted |
|---|---|---|---|---|
| Started | 9 | 9 | 9 | 9 |
| Completed | 9 | 9 | 9 | 9 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Crizotinib 250 mg IRT Fasted, PIC Fasted, CIC Fasted, CIC Fed | Crizotinib 250 mg PIC Fasted, CIC Fed, IRT Fasted, CIC Fasted | Crizotinib 250 mg CIC Fasted, IRT Fasted, CIC Fed, PIC Fasted | Crizotinib 250 mg CIC Fed, CIC Fasted, PIC Fasted, IRT Fasted |
|---|---|---|---|---|
| Started | 9 | 9 | 9 | 9 |
| Completed | 9 | 9 | 9 | 9 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Crizotinib 250 mg IRT Fasted, PIC Fasted, CIC Fasted, CIC Fed | Crizotinib 250 mg PIC Fasted, CIC Fed, IRT Fasted, CIC Fasted | Crizotinib 250 mg CIC Fasted, IRT Fasted, CIC Fed, PIC Fasted | Crizotinib 250 mg CIC Fed, CIC Fasted, PIC Fasted, IRT Fasted |
|---|---|---|---|---|
| Started | 9 | 9 | 9 | 9 |
| Completed | 9 | 9 | 9 | 9 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Crizotinib 250 mg IRT Fasted, PIC Fasted, CIC Fasted, CIC Fed | Crizotinib 250 mg PIC Fasted, CIC Fed, IRT Fasted, CIC Fasted | Crizotinib 250 mg CIC Fasted, IRT Fasted, CIC Fed, PIC Fasted | Crizotinib 250 mg CIC Fed, CIC Fasted, PIC Fasted, IRT Fasted |
|---|---|---|---|---|
| Started | 9 | 9 | 9 | 9 |
| Completed | 9 | 8 | 9 | 9 |
| Not completed | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Milestone | Crizotinib 250 mg IRT Fasted, PIC Fasted, CIC Fasted, CIC Fed | Crizotinib 250 mg PIC Fasted, CIC Fed, IRT Fasted, CIC Fasted | Crizotinib 250 mg CIC Fasted, IRT Fasted, CIC Fed, PIC Fasted | Crizotinib 250 mg CIC Fed, CIC Fasted, PIC Fasted, IRT Fasted |
|---|---|---|---|---|
| Started | 9 | 8 | 9 | 9 |
| Completed | 9 | 8 | 9 | 8 |
| Not completed | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 |
| Milestone | Crizotinib 250 mg IRT Fasted, PIC Fasted, CIC Fasted, CIC Fed | Crizotinib 250 mg PIC Fasted, CIC Fed, IRT Fasted, CIC Fasted | Crizotinib 250 mg CIC Fasted, IRT Fasted, CIC Fed, PIC Fasted | Crizotinib 250 mg CIC Fed, CIC Fasted, PIC Fasted, IRT Fasted |
|---|---|---|---|---|
| Started | 9 | 8 | 9 | 8 |
| Completed | 8 | 8 | 9 | 8 |
| Not completed | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 |
AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).
| ng*hr/mL | Crizotinib IRT Fasted | Crizotinib PIC Fasted | Crizotinib CIC Fasted | Crizotinib CIC Fed |
|---|---|---|---|---|
| Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0 - ∞]) | 2890.0 ± 1021.8 | 2665.0 ± 1190.4 | 2887.0 ± 1109.6 | 2475.0 ± 1037.7 |
Area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration (AUClast).
| ng*hr/mL | Crizotinib IRT Fasted | Crizotinib PIC Fasted | Crizotinib CIC Fasted | Crizotinib CIC Fed |
|---|---|---|---|---|
| Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) | 2763.0 ± 989.0 | 2531.0 ± 1158.0 | 2761.0 ± 1078.4 | 2359.0 ± 1013.0 |
| hr | Crizotinib IRT Fasted | Crizotinib PIC Fasted | Crizotinib CIC Fasted | Crizotinib CIC Fed |
|---|---|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) | 5.00 (1.00 to 8.00) | 5.00 (2.00 to 6.00) | 5.00 (2.00 to 6.00) | 5.00 (1.00 to 8.00) |
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
| hr | Crizotinib IRT Fasted | Crizotinib PIC Fasted | Crizotinib CIC Fasted | Crizotinib CIC Fed |
|---|---|---|---|---|
| Plasma Decay Half Life (t1/2) | 34.62 ± 4.13 | 35.28 ± 6.39 | 34.85 ± 4.94 | 35.41 ± 5.49 |
| ng/mL | Crizotinib IRT Fasted | Crizotinib PIC Fasted | Crizotinib CIC Fasted | Crizotinib CIC Fed |
|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) | 126.00 ± 36.58 | 119.30 ± 50.88 | 135.00 ± 47.84 | 116.10 ± 45.58 |
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
| L/hr | Crizotinib IRT Fasted | Crizotinib PIC Fasted | Crizotinib CIC Fasted | Crizotinib CIC Fed |
|---|---|---|---|---|
| Apparent Oral Clearance (CL/F) | 86.49 ± 30.42 | 93.78 ± 49.80 | 86.57 ± 53.63 | 101.00 ± 38.60 |
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
| L | Crizotinib IRT Fasted | Crizotinib PIC Fasted | Crizotinib CIC Fasted | Crizotinib CIC Fed |
|---|---|---|---|---|
| Apparent Volume of Distribution (Vz/F) | 4290.0 ± 1672.4 | 4703.0 ± 2874.7 | 4313.0 ± 3880.9 | 5096.0 ± 2302.0 |
Area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration (AUClast) of Crizotinib metabolite (PF-06260182).
| ng*hr/mL | Crizotinib IRT Fasted | Crizotinib PIC Fasted | Crizotinib CIC Fasted | Crizotinib CIC Fed |
|---|---|---|---|---|
| Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Crizotinib Metabolite (PF-06260182) | 432.20 ± 219.76 | 391.20 ± 255.12 | 436.90 ± 246.34 | 325.00 ± 192.81 |
AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).
| ng*hr/mL | Crizotinib IRT Fasted | Crizotinib PIC Fasted | Crizotinib CIC Fasted | Crizotinib CIC Fed |
|---|---|---|---|---|
| Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0 - ∞]) for Crizotinib Metabolite (PF-06260182) | 442.00 ± 221.96 | 402.10 ± 257.39 | 447.10 ± 248.23 | 341.80 ± 194.91 |
| ng/mL | Crizotinib IRT Fasted | Crizotinib PIC Fasted | Crizotinib CIC Fasted | Crizotinib CIC Fed |
|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) for Crizotinib Metabolite (PF-06260182) | 32.20 ± 12.48 | 29.74 ± 15.19 | 33.04 ± 12.12 | 23.64 ± 10.85 |
| hr | Crizotinib IRT Fasted | Crizotinib PIC Fasted | Crizotinib CIC Fasted | Crizotinib CIC Fed |
|---|---|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) for Crizotinib Metabolite (PF-06260182) | 6.00 (4.00 to 8.02) | 6.00 (4.00 to 8.00) | 5.00 (4.00 to 10.00) | 6.00 (2.00 to 10.00) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Crizotinib IRT Fasted | — | 0/36 (0%) | 21/36 (58.3%) |
| Crizotinib PIC Fasted | — | 0/36 (0%) | 24/36 (66.7%) |
| Crizotinib CIC Fasted | — | 0/36 (0%) | 20/36 (55.6%) |
| Crizotinib CIC Fed | — | 0/36 (0%) | 21/36 (58.3%) |
| Event | Crizotinib IRT Fasted | Crizotinib PIC Fasted | Crizotinib CIC Fasted | Crizotinib CIC Fed |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 9/36 | 13/36 | 13/36 | 13/36 |
| NauseaGastrointestinal disorders | 5/36 | 10/36 | 2/36 | 5/36 |
| FatigueGeneral disorders | 3/36 | 5/36 | 2/36 | 1/36 |
| HeadacheNervous system disorders | 4/36 | 5/36 | 4/36 | 3/36 |
| NasopharyngitisInfections and infestations | 2/36 | 3/36 | 0/36 | 1/36 |
| SomnolenceNervous system disorders | 1/36 | 1/36 | 1/36 | 3/36 |
| Abdominal painGastrointestinal disorders | 0/36 | 1/36 | 0/36 | 2/36 |
| Abdominal pain upperGastrointestinal disorders | 2/36 | 1/36 | 1/36 | 1/36 |
| Epigastric discomfortGastrointestinal disorders | 2/36 | 1/36 | 2/36 | 0/36 |
| Gastrointestinal sounds abnormalGastrointestinal disorders | 1/36 | 0/36 | 1/36 | 2/36 |
| Age Continuous(years) | Entire Study Population |
|---|---|
| Mean | 38.9 ± 8.1 |
| Sex: Female, Male(Participants) | Entire Study Population |
|---|---|
| Female | 0 |
| Male | 36 |
The record gives a start of Aug 2010, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2011, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Crizotinib